HPV vaccine: Cervarix

Bibliography

• Ferlay J, Bray P, Pizani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. IARC Press, Lyon, France; 2004
   Google Scholar
• Peto J, Gilham C, Fletcher O, Matthews FE. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004;364(9430):249-56
   PubMed Web of Science ®Google Scholar
• Arbyn M, Kyrgiou M, Simoens C, Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008;337:a1284
   PubMed Web of Science ®Google Scholar
• French DP, Maissi E, Marteau TM. Psychological costs of inadequate cervical smear test results. Br J Cancer 2004;91(11):1887-92
   PubMed Web of Science ®Google Scholar
• Cohen J. Public health. High hopes and dilemmas for a cervical cancer vaccine. Science 2005;308(5722):618-21
   PubMed Web of Science ®Google Scholar
• Lerman C, Miller SM, Scarborough R, Adverse psychologic consequences of positive cytologic cervical screening. Am J Obstet Gynecol 1991;165(3):658-62
   PubMed Web of Science ®Google Scholar
• Wolstenholme JL, Whynes DK. Stage-specific treatment costs for cervical cancer in the United Kingdom. Eur J Cancer 1998;34(12):1889-93
   PubMed Web of Science ®Google Scholar
• Jacob M, Broekhuizen FF, Castro W, Sellors J. Experience using cryotherapy for treatment of cervical precancerous lesions in low-resource settings. Int J Gynaecol Obstet 2005;89(Suppl 2):S13-20
   Google Scholar
• Walboomers JM, Jacobs MV, Manos MM, Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9
   PubMed Web of Science ®Google Scholar
• Collins Y, Einstein MH, Gostout BS, Cervical cancer prevention in the era of prophylactic vaccines: a preview for gynecologic oncologists. Gynecol Oncol 2006;102(3):552-62
   PubMed Web of Science ®Google Scholar
• Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24(Suppl 3):S11-25
   Google Scholar
• Giuliano AR, Tortolero-Luna G, Ferrer E, Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions. Vaccine 2008;26(Suppl 10):K17-28
   PubMedGoogle Scholar
• Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102(5A):3-8
   PubMedGoogle Scholar
• Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24(Suppl 3): S3/35-41
   PubMedGoogle Scholar
• Brown RE, Breugelmans JG, Theodoratou D, Benard S. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22(4):663-70
   PubMed Web of Science ®Google Scholar
• Stanley M. Immune responses to human papillomavirus. Vaccine 2006;24(Suppl 1):S16-22
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol Oncol 2008;110(3 Suppl 1):S1-10
   Google Scholar
• Viscidi RP, Schiffman M, Hildesheim A, Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent hpv infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004;13(2):324-7
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler C, Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364(9447):1757-65
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6(5):271-8
   PubMed Web of Science ®Google Scholar
• Boland G, Beran J, Lievens M, Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 2004;23(3):316-20
   PubMed Web of Science ®Google Scholar
• Pedersen C, Petaja T, Strauss G, Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007;40(6):564-71
   PubMed Web of Science ®Google Scholar
• Harper DM, Franco EL, Wheeler CM, Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367(9518):1247-55
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial (Patricia trial). Lancet 2007;369(9580):2161-70
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374(9686):301-14
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95(11):1459-66
   PubMed Web of Science ®Google Scholar
• Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007;369(9576):1861-8
   PubMed Web of Science ®Google Scholar
• Joura EA, Leodolter S, Hernandez-Avila M, Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 2007;369(9574):1693-702
   PubMed Web of Science ®Google Scholar
• Koutsky L. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27
   PubMed Web of Science ®Google Scholar
• Einstein MH, Schiller JT, Viscidi RP, Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 2009;9(6):347-56
   PubMed Web of Science ®Google Scholar
• Schwarz TF SM, Schneider A, Wysocki J, et al; HPV Study Group for Adult Women. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27(4):581-7
   PubMed Web of Science ®Google Scholar
• Romanowski B. Sustained efficacy and immunogenicity of the human papillomavirus (HPV) - 16/18 ASO4-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-85
   PubMed Web of Science ®Google Scholar
• De Carvalho NS, Roteli-Martins CM, Teixeira J, Immunogenicity and safety of HPV 16/18 AS04 adjuvanted vaccine up to 7.3 years. 25th International Papillomavirus Conference; Malmo, Sweden; 2009
   Google Scholar
• Giannini SL, Hanon E, Moris P, Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006;24(33-34):5937-49
   PubMed Web of Science ®Google Scholar
• Einstein MH, Baron M, Levin MJ, Comparison of the immunogenicity and safety of cervarix() and gardasil((R)) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18 – 45 years. Hum Vaccin 2009;5(10):705-19
   PubMed Web of Science ®Google Scholar
• David MP, Van Herck K, Hardt K, Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 2009 [Epub ahead of print]; doi:10.1016/ j.ygyno.2009.01.011)
   Google Scholar
• Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009;200(2):166-71
   PubMed Web of Science ®Google Scholar
• Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 2008;110(3 Suppl 1):S18-25
   Google Scholar
• Koshiol J, Lindsay L, Pimenta JM, Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008;168(2):123-37
   PubMed Web of Science ®Google Scholar
• Skinner R, Apter D, Chow S, Cross protective efficacy of Cervarix™ against oncogenic HPV types beyond HPV-16/18. 25th International Papillomavirus Conference; Malmo, Sweden; 2009
   Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16 – 26 years. J Infect Dis 2009;199(7):926-35
   PubMed Web of Science ®Google Scholar
• Gardasil. Summary of product characteristics, UK. Available from: http://emc.medicines.org.uk/document.aspx?documentId=19016 (last updated 25 September 2009)
   Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K, The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16 – 26 years. J Infect Dis 2009;199(7):936-44
   PubMed Web of Science ®Google Scholar
• Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States–a 24-year population-based study. Gynecol Oncol 2000;78(2):97-105
   PubMed Web of Science ®Google Scholar
• Bosch FX, Burchell AN, Schiffman M, Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008;26(Suppl 10):K1-16
   PubMed Web of Science ®Google Scholar
• Einstein M, Baron M, Levin M, ; on behalf of the HPV-010 Study Group. Comparative evaluation of immunogenicity of two prophylactic human papillomavirus cervical cancer vaccines. 16th International meeting of the European Society of Gynaecological Oncology (ESGO); 11 – 14 October 2009; Belgrade, Serbia
   Google Scholar
• Pichichero M. Booster vaccinations: can immunologic memory outpace disease pathogenesis? Pediatrics 2009;124(6);1633-41
   PubMed Web of Science ®Google Scholar
• Einstein MH. Acquired immune response to oncogenic human papillomavirus associated with prophylactic cervical cancer vaccines. Cancer Immunol Immunother 2008;57(4):443-51
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsague X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008;26(Suppl 10):K53-61
   Google Scholar
• Descamps D, Hardt K, Spiessens B, Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009;5(5):332-40
   PubMed Web of Science ®Google Scholar
• Verstraeten T, Descamps D, David MP, Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008;26(51):6630-8
   PubMed Web of Science ®Google Scholar
• Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (gardasil). Drugs 2006;66(9):1263-71; discussion 72-3
   PubMed Web of Science ®Google Scholar
• Munoz N, Manalastas R Jr, Pitisuttithum P, Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24 – 45 years: a randomised, double-blind trial. Lancet 2009;373(9679):1949-57
   PubMed Web of Science ®Google Scholar
• Franco EL, Villa LL, Sobrinho JP, Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999;180(5):1415-23
   PubMed Web of Science ®Google Scholar
• Munoz N, Mendez F, Posso H, Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190(12):2077-87
   PubMed Web of Science ®Google Scholar
• Coupe VM, Berkhof J, Bulkmans NW, Age-dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008;98(3):646-51
   PubMed Web of Science ®Google Scholar
• Sellors JW, Karwalajtys TL, Kaczorowski J, Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 2003;168(4):421-5
   PubMed Web of Science ®Google Scholar
• Grainge MJ, Seth R, Guo L, Cervical human papillomavirus screening among older women. Emerg Infect Dis 2005;11(11):1680-5
   PubMed Web of Science ®Google Scholar
• Clifford GM, Gallus S, Herrero R, Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005;366(9490):991-8
   PubMed Web of Science ®Google Scholar
• Castellsagué X SA, Kaufmann AM, Bosch FX. HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives. Gynecol Oncol 2009;115:S15-23
   Google Scholar
• Cuschieri KS, Horne AW, Szarewski A, Cubie HA. Public awareness of human papillomavirus. J Med Screen 2006;13(4):201-7
   PubMed Web of Science ®Google Scholar
• Miura S, Matsumoto K, Oki A, Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 2006;119(11):2713-5
   PubMed Web of Science ®Google Scholar
• Denny L, Boa R, Williamson AL, Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol 2008;111(6):1380-7
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Weinberg A, Song L-Y, Safety and immunogenicity of gardasil in HIV-infected children. 25th International Papillomavirus Conference; Malmo, Sweden; 2009
   Google Scholar
• Eggertson L. Three provinces to study 2-dose HPV vaccine. CMAJ 2007;177(5):444-5
   PubMed Web of Science ®Google Scholar
• Dobson S, Dawar M, Scheifele D, Are 2 doses of HPV vaccine adequate in girls? 25th International Papillomavirus Conference; Malmo, Sweden; 2009
   Google Scholar
• Kane MA. Human papillomaviruses (HPV) vaccines: implementation and communication issues. J Fam Plann Reprod Health Care 2008;34(1):3-4
   PubMed Web of Science ®Google Scholar
• Michels KB, Hausen HZ. HPV vaccine for all. Lancet 2009;374(9686):268-70
   PubMed Web of Science ®Google Scholar
• Szarewski A. HPV vaccines: peering through the fog. J Fam Plann Reprod Health Care 2008;34(4):207-9
   PubMed Web of Science ®Google Scholar
• Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002;13(6):631-9
   PubMed Web of Science ®Google Scholar
• Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005;191(Suppl 1):S97-106
   Google Scholar
• Bottiger M, Forsgren M. Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women postpartum) and 13 years of a general two-dose vaccination. Vaccine 1997;15(14):1538-44
   PubMed Web of Science ®Google Scholar
• Kim J. Mathematical model of HPV provides insight into impacts of risk factors and vaccine. PLoS Med 2006;3(5):e164
   Google Scholar
• Martin F, Bower M. Anal intraepithelial neoplasia in HIV positive people. Sex Transm Infect 2001;77(5):327-31
   PubMed Web of Science ®Google Scholar
• Giuliano A, Palefsky J. Quadrivalent HPV vaccine efficacy against male genital disease and infection. 25th International Papillomavirus Conference; Malmo, Sweden; 2009
   Google Scholar
• Szarewski A. Raising awareness of human papillomavirus and cervical cancer prevention: the need for clinical education (in press). Future Virol 2009;4(5):431-6
   Web of Science ®Google Scholar
• Le Tallec D, Doucet D, Elouahabi A, Cervarix, the GSK HPV-16/HPV-18 AS04-adjuvanted cervical cancer vaccine, demonstrates stability upon long-term storage and under simulated cold chain break conditions. Hum Vaccin 2009;5(7):467-74
   PubMed Web of Science ®Google Scholar
• Schiller J, Nardelli-Haefliger D. Second generation HPV vaccines to prevent cervical cancer. Vaccine 2006;24(S3):147-53
   Google Scholar
• Bosch FX CX, de Sanjose S. HPV and cervical cancer: screening or vaccination? Br J Cancer 2008;98:15-21
   PubMed Web of Science ®Google Scholar